Colorectal Cancer News and Research RSS Feed - Colorectal Cancer News and Research

Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.
Moffitt researchers hope to improve pancreatic cancer survival rates by developing blood test to identify IPMNs

Moffitt researchers hope to improve pancreatic cancer survival rates by developing blood test to identify IPMNs

Pancreatic cancer is the fourth most common cause of cancer-related death in the United States and has a 5-year survival rate of only 6 percent, which is the lowest rate of all types of cancer according to the American Cancer Society. [More]
Researchers identify druggable target to potentially root out colon cancer, end relapse

Researchers identify druggable target to potentially root out colon cancer, end relapse

Researchers targeting colorectal cancer stem cells - the root cause of disease, resistance to treatment and relapse - have discovered a mechanism to mimic a virus and potentially trigger an immune response to fight the cancer like an infection. [More]
Obesity raises Lynch syndrome CRC risk

Obesity raises Lynch syndrome CRC risk

Obesity increases the risk of colorectal cancer in patients with Lynch syndrome, research indicates, but daily aspirin use may combat this excess risk. [More]
Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells' ability to avoid detection and destruction by the immune system. [More]
New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

New study describes multi-method strategy to improve detection of PMS2 gene mutations in Lynch syndrome

About 3% of colorectal cancers are due to Lynch syndrome, an inherited cancer susceptibility syndrome that predisposes individuals to various cancers. Close blood relatives of patients with Lynch syndrome have a 50% chance of inheritance. The role that PMS2 genetic mutations play in Lynch syndrome has been underestimated in part due to technological limitations. [More]
Longer-lasting colonoscopies associated with lower cancer rates

Longer-lasting colonoscopies associated with lower cancer rates

If a colonoscopy seems like the type of thing you'd like to get done with quickly, think again. Research by a Veterans Affairs team has confirmed that longer-lasting colonoscopies are associated with lower cancer rates. [More]
Study reveals how inflammation triggers colon cancer cells to metastasize

Study reveals how inflammation triggers colon cancer cells to metastasize

A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois, M.D., Ph.D., has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize. [More]
Researchers find way to screen blood samples to detect presence of precancerous polyps in the colon

Researchers find way to screen blood samples to detect presence of precancerous polyps in the colon

Canadian researchers have found a way to screen blood samples for molecular traces that indicate the presence of precancerous polyps in the colon, a key warning sign for colon cancer. Their results, published this week in the journal Biomedical Optics Express, from The Optical Society, may yield a cheaper and less invasive initial screening test for colon cancer that could complement colonoscopy, though further clinical trials will need to demonstrate the safety and effectiveness of the blood test before it is routinely used. [More]
Three medical oncologists to receive ESMO's acclaimed awards

Three medical oncologists to receive ESMO's acclaimed awards

The European Society for Medical Oncology, the leading European professional organisation for advancing medical oncology, announced today the three exceptional medical oncologists who will receive its acclaimed awards. [More]
Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated. [More]
PHD1 inhibition may have therapeutic potential for colorectal cancer

PHD1 inhibition may have therapeutic potential for colorectal cancer

Scientists at VIB and KU Leuven have shown that blocking the PHD1 oxygen sensor hinders the activation of p53, a transcription factor that aids colorectal cancer (CRC) cells in repairing themselves and thus resisting chemotherapy. Chemotherapy resistance remains a major clinical issue in the treatment of CRC. These findings indicate that PHD1 inhibition may have valuable therapeutic potential. The study was published in the leading medical journal EMBO Molecular Medicine, which features molecular biology-driven research. [More]
EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia. [More]
VolitionRx reports net loss of $1.9 million for second quarter 2015

VolitionRx reports net loss of $1.9 million for second quarter 2015

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the second quarter ended June 30, 2015. [More]
CSN6 protein linked to poor survival among patients with colorectal cancer

CSN6 protein linked to poor survival among patients with colorectal cancer

A protein called CSN6 has been found to be correlated with poor survival among patients with colorectal cancer, according to a study at The University of Texas MD Anderson Cancer Center. [More]
Penn research reveals additional pathway for origin of colon cancer

Penn research reveals additional pathway for origin of colon cancer

Cancer researchers already know of some oncogenes and other factors that promote the development of colon cancers, but they don't yet have the full picture of how these cancers originate and spread. Now researchers from the Perelman School of Medicine at the University of Pennsylvania have illuminated another powerful factor in this process. [More]
CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands. [More]
Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. [More]
VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests. [More]
Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. [More]
Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

An algorithm dubbed ENVE could be the Google for genetic aberrations — and it comes from Case Western Reserve. [More]
Advertisement